Addex Therapeutics Ltd (ADXN)

CH — Healthcare Sector
Peers: IPHA  APM  CYAD  DYAI  ACGN  ERYP  SNGX  ATXI  KRON  CYCN  LRMR  ACHL 

Automate Your Wheel Strategy on ADXN

With Tiblio's Option Bot, you can configure your own wheel strategy including ADXN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ADXN
  • Rev/Share 0.0057
  • Book/Share 0.1134
  • PB 0.4841
  • Debt/Equity 0.004
  • CurrentRatio 4.5878
  • ROIC -0.6504

 

  • MktCap 5399073.7796
  • FreeCF/Share -0.0613
  • PFCF -0.9037
  • PE 0.9908
  • Debt/Assets 0.0036
  • DivYield 0
  • ROE 0.9206

 

  • Rating A
  • Score 4
  • Recommendation Buy
  • P/E Score 3
  • DCF Score 1
  • P/B Score 4
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies
ADXN
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today partner Indivior has successfully advanced its GABAB positive allosteric modulator (PAM) program through IND enabling studies.

Read More
image for news Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies
Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery
ADXN
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it has entered into an option- and collaboration agreement with Sinntaxis AB (www.sinntaxis.com) for an exclusive license to intellectual property covering the use of metabotropic glutamate receptor subtype 5 (mGlu5) inhibitors for the treatment of brain injury recovery.

Read More
image for news Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery

About Addex Therapeutics Ltd (ADXN)

  • IPO Date 2020-02-12
  • Website https://www.addextherapeutics.com
  • Industry Biotechnology
  • CEO Mr. Timothy Mark Dyer
  • Employees 23
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.